Baird Financial Group
AXSM icon

Baird Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Baird Financial Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
+10,202
New +$2.21M ﹤0.01% 1019
2024
Q4 		– Sell
-10,118
Closed -$909K – 1750
2024
Q3 		$909K Buy
+10,118
New +$883K ﹤0.01% 1204

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Baird Financial Group's AXSM Position: Q2 2026 in Review

Baird Financial Group opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 10,202 shares worth $2.5M. The stake represents ﹤0.01% of the portfolio and ranks #1019 among its holdings. This is a return to the name: Baird Financial Group previously reported a position in AXSM as recently as Q3 2024.

Baird Financial Group first reported a position in AXSM in Q3 2024 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Baird Financial Group held 10,202 shares of Axsome Therapeutics worth $2.5M as of Q2 2026.
  • Axsome Therapeutics was a new Baird Financial Group position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1019 holding.
  • Baird Financial Group first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.